Biodextris

#1 Biopharmaceutical Manufacturing Firm in Laval, Quebec 

Struggling with Analytical, Development, & Bioproduction Challenges?

Overcome challenges in analytical, development, and bioproduction with Biodextris. Our expertise accelerates your biologics and small molecule products from concept to market. Let’s streamline your journey.

About Biodextris

The Biodextris Team has worked together in mid and large sized vaccine companies for the past 18 years, now offering our big pharma expertise in a more personal and interactive package. We develop, manufacture and test a wide range of biologic products for vaccine, pharmaceutical and other applications.

Providing High Quality Clinical Development

The Way a CDMO should be

One-stop Partner

With Biodextris, your project is overseen by dedicated project managers with extensive hands-on experience, saving you time and enhancing your experience.

Extensive Vaccines And Biologics Experience

Dedicated Project Managers

Comprehensive Analytical Services

Collaborative With Regular Feedback

Development Strategy Input

CGMP Manufacturing Suite

Book an Appointment

We offer a full array of cell based production for Biological products.

With Biodextris, your project is overseen by dedicated project managers with extensive hands-on experience, saving you time and enhancing your experience. We offer technical and quality guidance, with cGMP compliant testing to ensure you successfully navigate the regulatory path for your product.

Proteins

Enzymes

Antibodies

Biosimilars

Peptides

Plasmids

Our services

Companies can rely on the Biodextris Team to deliver excellent services for a wide range of biologic products.

Our history leaves us with the know-how for high quality, robust, commercial product development combined with flexibility and the sense of urgency inherent in smaller organizations. From Analytical Development to Quality Management, our team of experienced product development scientists will get you through your project.

Analytical Services

Skilled experts in developing complete analytical packages for novel and complex vaccines, biologics and small molecules.


Explore Analytical services

Development Services

Rapid delivery of robust and reliable production processes ready for manufacturing of your vaccine or biologic.

Upstream Process

Downstream Purification

Process Transfer


Explore Development Services

Bioproduction Services

Production services provide high-quality cGMP material for research, preclinical or clinical investigations.

Quality Documentation And Characterization Packages

Bl2 Production Capabilities

Glp Toxicology Lots


Explore Bioproduction Services

Your Health And Safety Is Important To Us

Get in Touch With Us

Drop us a Message

Please feel welcome to contact our friendly reception staff with any enquiry. We will answer to you shortly!

Contact - Contact Us

Recent Articles

Tips, News and Updates

December 17, 2024
Quebec City, December 17th, 2024 – Aramis Biotechnologies Inc. ("Aramis"), a Quebec City-based company specialized in plant-based biomanufacturing of innovative vaccines, and Biodextris Inc. (“Biodextris”), a Montreal-based CDMO specialized in cGMP complex biologic products, are excited to announce the signature of an agreement. This strategic partnership will leverage the expertise of both companies to ensure efficient downstream manufacturing of clinical materials for Aramis’ leading product candidate, a seasonal influenza vaccine with the potential to improve the protection of at-risk populations. Under the terms of the agreement, Biodextris will provide Aramis with access to its state-of-the-art facilities and industry-leading capabilities to ensure the timely production of high-quality materials for Aramis’ forthcoming Phase 1 & 2 clinical trials. The downstream manufacturing agreement marks an important milestone in the ongoing collaboration between Aramis and Biodextris, combining cutting-edge science and manufacturing excellence to drive success in clinical development. "We are delighted to be working with Biodextris as partner for downstream manufacturing and supply of clinical material" said Aramis’ Co-founder & CEO, Frédéric Ors. "This partnership is aligned with Aramis’ business model to use the best external expertise and capabilities, and prepare operations scale-up for potential pandemic response. From the initial proposal through to the extensive collaboration to date, we’ve been impressed by Biodextris’ partnership-centric approach to identifying and solving technical challenges, as well as their commitment to the highest quality standards, making them an ideal partner for clinical-scale production of our influenza vaccine candidate.” "It’s a pleasure to be chosen as Aramis’ development and downstream manufacturing partner in their mission to revolutionize vaccines” says Cédric Héroux, Biodextris’ GM. “The Aramis team’s deep scientific expertise and passion for health impact, both in Canada and at a global level, has resonated deeply with Biodextris since the start of our collaboration, and we look forward to working with them to make these vaccines accessible to patients.” About Aramis Biotechnologies Based in Quebec City, Aramis Biotechnologies is a Canadian company founded in 2023 that specializes in plant-based production of innovative vaccines. As a majority employee-owned company, our ambition is to develop innovative and sustainable solutions to current and future public health challenges. The Aramis’ team is grateful for the support from Innovation, Sciences and Economic Development Canada and from the City of Quebec. About Biodextris Inc. Biodextris is a cGMP complex biologics CDMO with over 20 years’ experience in the development, GMP manufacturing, and bioanalysis of high-value complex biologic products. With customers ranging from the largest global Biopharmaceutical companies to university spin-outs, Biodextris is the partner of choice for innovative Biotechnology companies with novel or complex processes looking to accelerate their path to clinic & commercialization. Biodextris’ new center of excellence in Laval, supporting customers in manufacturing and analysis from pre-clinical development through to commercialization, was developed with the support of the governments of Quebec and Canada, as well as Investissement Québec. For more information: aramisbiotechnologies.com biodextris.com
Biodextris Inc. inaugurates its new facilities in the heart of Laval's Biotech City
By Philippe Beland October 9, 2024
Laval, October 4, 2024 – In the presence of Annie Koutrakis, Member of Parliament for Vimy and Parliamentary Secretary to the Honourable Soraya Martinez Ferrada, Minister of Tourism and Minister responsible for Canada Economic Development Regions for Quebec regions, Christopher Skeete, Minister for the Economy, Minister Responsible for the Fight Against Racism, and Minister Responsible for the Laval Region, and Guylaine Rose, Regional Director for Laval and Outaouais at Investissement Québec, Biodextris Inc. proudly inaugurates its brand new laboratories in the heart of Laval's Biotech City. These new facilities, resulting from nearly $25 million in investments, mark the beginning of a new era for the Quebec-based company specializing in the development, clinical manufacturing, and packaging of vaccines and biologics for biotech and pharmaceutical companies. “We are extremely proud to inaugurate these new facilities. This move represents much more than a simple change of location; it symbolizes our commitment to innovation and our desire to continue growing while remaining true to our customer-focused approach centered on human relationships,” said Cédric Héroux, CEO of Biodextris. Founded in 2015, Biodextris Inc. was the initiative of three entrepreneurial scientists from Quebec. Following the closure of GSK's enterprise and leveraging the company’s legacy, the founders chose to persevere and continue certain operations locally, ensuring the retention of high-quality jobs. Today, Biodextris Inc. employs over 40 people and stands out for its professionalism, personalized customer approach, and expertise in working with complex products. The pandemic, which refocused global attention on biotechnology-based vaccines and treatments, spurred the company's expansion. This growth phase reflects Biodextris' remarkable commitment to excellence and its mission to contribute to the advancement of Quebec’s life sciences industry. Located in the heart of Laval’s Biotech City, the custom-designed facility was built to meet Biodextris’ specific needs. The project received $4 million in support from the ESSOR program, administered by Investissement Québec on behalf of the Government of Quebec, along with an additional $3 million directly from Investissement Québec. Furthermore, the Government of Canada, through CED, is providing $900,000. “Investissement Québec is proud to support companies that strengthen Quebec’s life sciences ecosystem. Biodextris' project illustrates what can be achieved when innovation and growth are at the heart of a company’s mission. This expansion will not only boost the company’s productivity but also address a strategic need within our economy,” said Bicha Ngo, President and CEO of Investissement Québec. These investments will allow Biodextris Inc. to quadruple its production capacity, expanding from 8,000 to 32,000 square feet, and increase its workforce from 44 to 65 employees over the next three to five years. Additionally, this expansion will introduce a new division dedicated to the development and production of clinical batches of biotherapeutics, utilizing messenger RNA and plasmid technologies. “Our government is proud to invest $4 million in Biodextris' cutting-edge new facilities. We will continue to support local companies that help Quebec shine in the life sciences sector,” said Christine Fréchette, Minister of the Economy, Innovation and Energy, and Minister Responsible for Regional Economic Development. “With its high-quality infrastructure and experienced professionals, Biodextris contributes to the vitality of Quebec’s life sciences industry. By supporting the development of their new facilities, we are reinforcing Laval’s role as a hub of innovation in this field,” said Christopher Skeete, Minister for the Economy, Minister Responsible for the Fight Against Racism, and Minister Responsible for the Laval Region. “Our government is committed to investing to ensure our SMEs remain competitive and innovative. Thanks to CED’s support, Biodextris will be able to increase its production capacity, improve its competitiveness and continue to foster innovation in the life sciences field. We are here to support workers and Quebec and Canadian SMEs by helping them equip themselves with what they need so that, together, we can build a stronger, more resilient, more sustainable economy,” stated Annie Koutrakis, Member of Parliament for Vimy and Parliamentary Secretary to the Minister of Tourism and Minister responsible for CED. The opening of Biodextris Inc.’s new facilities not only illustrates the company’s success but also its ongoing commitment to innovation and excellence in life sciences, showcasing Quebec’s supportive environment for the development of such enterprises. “The inauguration of Biodextris Inc.’s new facilities in Laval is a source of pride for our city. It underscores our commitment to supporting innovation and economic development in the life sciences sector. We are thrilled to welcome this important expansion, which further strengthens our position as a leading Biotech City,” said Stéphane Boyer, Mayor of Laval. About Biodextris Inc. Founded in 2015, Biodextris Inc. is a subsidiary of Clean Biologics SAS, which provides clinical manufacturing process analysis and development services and quality control testing for clients in the vaccine and biologics industries. The company is staffed by experienced biologics development scientists, and key team members have worked together in medium and large vaccine development and manufacturing companies for almost twenty years. The Biodextris team provides its extensive pharmaceutical company expertise in a more personal and interactive setting to clients of various sizes. The company develops, manufactures, and tests a wide range of biological products for vaccine, pharmaceutical, and other applications. Biodextris has the experience and expertise to develop high-quality, robust, and marketable products, while acting with the flexibility and sense of urgency required by small organizations.
cGMP biomanufacturing facility Laval
June 5, 2024
Discover Biodextris' new cGMP biomanufacturing and analytical facility. Check out our state-of-the-art capabilities.
Share by: